Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Veracyte (VCYT)

Veracyte raises 2026 revenue guidance as Q2 revenue rises 15% to $150.3 million

Positive Impact 4 of 5 guidance Written later

Veracyte reported second-quarter 2026 total revenue of $150.3 million, up 15% from a year earlier, and GAAP net income of $25.5 million, or $0.31 per diluted share, compared with a net loss of $980,000 a year earlier. The company raised its 2026 total revenue guidance to $590 million to $596 million, which signals stronger expected growth for shareholders.

Key points

  • Total revenue rose 15% to $150.3 million; testing revenue rose 19% to $145.7 million
  • GAAP net income was $25.5 million, or $0.31 per diluted share, versus a net loss of $980,000 in Q2 2025
  • 2026 total revenue guidance raised to $590 million to $596 million from $582 million to $592 million
  • Cash, cash equivalents and short-term investments totaled $485.2 million as of June 30, 2026

The filing

CompanyVeracyte (VCYT)
Form8-K, current report
Filed with the SECJul 30, 2026, 4:18 PM ET
Accession number0001384101-26-000042

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:55 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 30, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.